<DOC>
	<DOCNO>NCT02002689</DOCNO>
	<brief_summary>The purpose signal seek study determine whether treatment LDE225 demonstrate sufficient efficacy hedgehog pathway-mutated solid tumor and/or hematologic malignancy warrant study</brief_summary>
	<brief_title>LDE225 Patients With PTCH1 SMO Mutated Tumors</brief_title>
	<detailed_description />
	<criteria>Patient confirm diagnosis select solid tumor ( except medulloblastoma , basal cell carcinoma pancreatic adenocarcinoma ) hematological malignancy ( except CML , ALL AML ) . Patient preidentified tumor PTCH1 SMO mutation . Patient receive least one prior treatment recurrent , metastatic /or locally advance disease standard therapy option anticipate result durable remission . Patient progressive measurable disease per RECIST 1.1. appropriate hematological guideline . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Patients receive prior treatment LDE225 . Patients neuromuscular disorder associate elevated CK ( i.e . inflammatory myopathy , muscular dystrophy , amyotrophic lateral sclerosis spinal muscular atrophy ) concomitant treatment drug recognize cause rhabdomyolysis Patients primary CNS tumor CNS tumor involvement Patient receive chemotherapy anticancer therapy ≤ 4 week prior start study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Solid tumor malignancy ,</keyword>
	<keyword>hematologic malignancy ,</keyword>
	<keyword>mutation , translocation ,</keyword>
	<keyword>signature ,</keyword>
	<keyword>PTCH1 ,</keyword>
	<keyword>SMO ,</keyword>
	<keyword>LDE225 ,</keyword>
	<keyword>endometrial cancer ,</keyword>
	<keyword>colon cancer ,</keyword>
	<keyword>bladder ,</keyword>
	<keyword>NSCLC</keyword>
</DOC>